Earnings ·
Cogent Biosciences reported second quarter 2026 financial results on August 10, 2026
COGTCogent Biosciences, Inc.
Cogent Biosciences reported second quarter 2026 financial results on August 10, 2026. The company posted a net loss of $96.4 million compared to $73.5 million in the prior year period. Research and development expenses increased to $70.8 million from $62.2 million, while general and administrative expenses rose significantly to $31.8 million from $13.4 million due to commercial readiness investments for bezuclastinib. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling $792.3 million. Including $73.6 million in gross proceeds from an at-the-market equity facility sold after quarter-end, Cogent expects its pro forma cash balance of $865.9 million to fund operations into late 2028. The filing also announced the approval of inducement equity grants for 59 new employees under Nasdaq Listing Rule 5635(c)(4). Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases.